false
0001725430
0001725430
2023-11-08
2023-11-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): November 8, 2023
INTELLIGENT
BIO SOLUTIONS INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-39825 |
|
82-1512711 |
(State
of
Incorporation) |
|
(Commission
File Number) |
|
(IRS
employer
identification no.) |
142
West, 57th Street, 11th
Floor
New
York, NY 10019
(Address
of principal executive offices, including zip code)
Registrant’s
telephone number, including area code: (646) 828-8258
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, $0.01 par value |
|
INBS |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.02 Results of Operations and Financial Condition.
On
November 8, 2023, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”)
announcing financial results for the three months ended September 30, 2023. A copy of the press release is furnished as Exhibit 99.1
to this Current Report on Form 8-K.
The
information contained herein and in the accompanying exhibits shall not be incorporated by reference into any filing of the Company,
whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated
by specific reference to such filing. The information in this report, including the exhibit hereto, shall not be deemed to be “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section
or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
November 8, 2023
|
INTELLIGENT
BIO SOLUTIONS INC. |
|
|
|
|
By:
|
/s/
Spiro Sakiris |
|
Name:
|
Spiro
Sakiris |
|
Title: |
Chief
Financial Officer |
Exhibit 99.1
Intelligent Bio Solutions Inc. Reports Fiscal 2024
First Quarter Financial Results and Operational Highlights
- First fiscal quarter revenue and government support
income increased 191% year-over-year and 88% sequentially due to strong organic growth and execution of expansion plans –
- Increased market share organically in existing
markets and entered South American market –
- Advanced plans for expansion into the U.S. market
–
- Completed
critical development milestone in plans to add new assays for ketamine and tramadol to the Intelligent Fingerprinting Drug Screening System
-
NEW YORK, November 08, 2023 – Intelligent
Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent,
rapid, non-invasive testing solutions, today announced its financial results for its fiscal first quarter ended September 30, 2023, and
provided a business update.
“We achieved strong revenue growth over the
first quarter of fiscal 2024, maintaining the momentum we have built over the past several quarters,” commented Harry Simeonidis,
President and Chief Executive Officer of Intelligent Bio Solutions Inc. “This growth is largely attributable to the increasing
acceptance of our proprietary Intelligent Fingerprinting Drug Screening System by customers, which has translated to consistent
sales and increased revenue. The sustained rising demand for our innovative screening product across a diverse number of industries demonstrates
its versatility and its value as a faster, more efficient, and less-invasive drug screening solution for workplaces.”
“We expanded our market presence in South America
while advancing our reach in existing markets. We are now focused on executing our plan to enter the U.S. market after receiving FDA guidance
on a regulatory pathway for our Intelligent Fingerprinting Drug Screening Cartridge earlier this year.” Mr. Simeonidis added.
First Quarter & Recent Highlights:
| ● | Expanded into the New Zealand market, representing a significant
milestone in the Company’s growth strategy for its Intelligent Fingerprinting Drug Screening System. |
| ● | Enhanced customer portfolio with specialist container logistics firm VKVP Haulage adopting the Company’s
Intelligent Fingerprinting Drug Screening System. Additionally, existing customer Auctus Management Group completed 25,000 tests using
the Company’s Intelligent Fingerprinting Drug Screening System. |
| ● | Obtained recertification for ISO
13485: 2016, which is the international standard for medical systems quality management system certification. |
| ● | Completed critical development milestone in plans to add new assays
for ketamine and tramadol to the Intelligent Fingerprinting Drug Screening System. The new assays passed the Company’s initial design
phase and are ready for scale-up and transfer to manufacture ahead of potential clinical trials. |
| ● | Secured eight new customers across Australia for its Intelligent
Fingerprinting Drug Screening System product. The customers come from a variety of industries
including mining, aviation, construction, manufacturing, and agriculture, and are using it to promote alternative screening practices. |
| ● | Signed a South American distribution deal with TSCOM SPA for the
Company’s Intelligent Fingerprinting Drug Screening System and secured its first order under this agreement. |
First Fiscal Quarter Ended September 30, 2023,
Financial Results
All amounts are expressed in U.S. dollars unless indicated
otherwise. All authorized, issued, and outstanding stock and per share amounts reflect the 1-for-20 reverse stock split effected by the
Company on February 9, 2023, unless indicated otherwise.
The Company’s combined revenue and government
support income increased by 191% to $0.91 million for the first fiscal quarter ended September 30, 2023, including revenue from sales
of goods of $0.8 million, compared to $0 in the first fiscal quarter ended September 30, 2022. The increase in revenue is due to the acquisition
of Intelligent Fingerprinting Ltd (“IFP”) in October 2022 and the launch of its Intelligent Fingerprinting Drug Screening
System in the Asia-Pacific region via Intelligent Bio Solutions (APAC) Pty Ltd.
Net loss attributable to INBS for the first fiscal
quarter ended September 30, 2023 was $2.4 million, compared to a net loss of $1.2 million for the first fiscal quarter of the prior fiscal
year. This increase is primarily driven by the combined results of operations after the acquisition of IFP offset by a recognition of
fair value gain on revaluation of holdback Series C Preferred Stock during the current quarter of $131,250.
The Company ended the quarter with cash and cash equivalents
of approximately $0.2 million. On October 4, 2023, subsequent to the quarter ended September 30,
2023, the Company raised approximately $4.378 million prior to deducting underwriting discounts and commissions and offering expenses
via a registered underwritten public offering of the Company’s securities. Net proceeds to the Company, after deducting the underwriting
discounts and commissions and estimated offering expenses payable by the Company, were approximately $3.35 million.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (the “Company”)
(Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that
its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has
the potential for broader applications in additional fields. This hygienic, and cost-effective system is designed to screen for recent
use of drugs commonly found in the workplace, including opioids, cocaine, methamphetamine, and cannabis. With sample collection in seconds
and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally,
the Company’s biosensor platform has the potential to test for up to 130 indications, ranging from glucose to immunological conditions
and communicable diseases. The Company’s current customer segments include construction, manufacturing and engineering, transport
and logistics firms, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc/
Forward-Looking Statements:
Some of the statements in this press release are forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release
include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its screening and
diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others.
Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as
of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking
statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including ‘‘believes,’’
‘‘estimates,’’ ‘‘anticipates,’’ ‘‘expects,’’ ‘‘plans,’’
‘‘projects,’’ ‘‘intends,’’ ‘‘potential,’’ ‘‘may,’’
‘‘could,’’ ‘‘might,’’ ‘‘will,’’ ‘‘should,’’
‘‘approximately’’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking
statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent
Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this
release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained
in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc
Media Contact:
Cheryl Billson
Comma Communications
cheryl.billson@commacomms.com
Investor Contact:
Valter Pinto
KCSA Strategic Communications
INBS@kcsa.com
Intelligent Bio Solutions Inc.
Condensed Consolidated Balance Sheets
(Amounts in US$)
| |
September 30, 2023 (Unaudited) | | |
June 30, 2023 | |
ASSETS | |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 186,401 | | |
$ | 1,537,244 | |
Accounts receivable, net | |
| 567,510 | | |
| 293,861 | |
Inventories, net | |
| 965,091 | | |
| 979,907 | |
Research and development tax incentive receivable | |
| 559,588 | | |
| 498,758 | |
Other current assets | |
| 413,305 | | |
| 552,791 | |
Total current assets | |
| 2,691,895 | | |
| 3,862,561 | |
Property and equipment, net | |
| 664,922 | | |
| 690,175 | |
Operating lease right-of-use assets | |
| 471,532 | | |
| 546,475 | |
Intangible assets, net | |
| 4,872,141 | | |
| 5,255,401 | |
TOTAL ASSETS | |
$ | 8,700,490 | | |
$ | 10,354,612 | |
| |
| | | |
| | |
LIABILITIES AND SHAREHOLDERS’ EQUITY | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable and accrued expenses | |
$ | 3,628,797 | | |
$ | 2,610,028 | |
Current portion of operating lease liabilities | |
| 227,414 | | |
| 223,447 | |
Current portion of deferred grant income | |
| 2,240,929 | | |
| 2,338,057 | |
Current employee benefit liabilities | |
| 406,964 | | |
| 358,942 | |
Current portion of notes payable | |
| 341,834 | | |
| 353,211 | |
Total current liabilities | |
| 6,845,938 | | |
| 5,883,685 | |
Employee benefit liabilities, less current portion | |
| 27,732 | | |
| 24,902 | |
Operating lease liabilities, less current portion | |
| 284,028 | | |
| 356,165 | |
Notes payable, less current portion | |
| 306,234 | | |
| 402,862 | |
Total liabilities | |
| 7,463,932 | | |
| 6,667,614 | |
Commitments and contingencies | |
| | | |
| | |
| |
| | | |
| | |
Shareholders’ equity: | |
| | | |
| | |
Common stock, $0.01 par value, 100,000,000 shares authorized, 2,330,399 shares issued and outstanding at September 30, 2023 and June 30, 2023, respectively | |
| 23,304 | | |
| 23,304 | |
Treasury stock, at cost, 1,386 shares as of September 30, 2023 and June 30, 2023, respectively | |
| (14 | ) | |
| (14 | ) |
Additional paid-in capital | |
| 46,158,763 | | |
| 46,158,763 | |
Accumulated deficit | |
| (44,232,777 | ) | |
| (41,807,573 | ) |
Accumulated other comprehensive loss | |
| (593,512 | ) | |
| (575,496 | ) |
Total consolidated Intelligent Bio Solutions Inc. equity | |
| 1,355,764 | | |
| 3,798,984 | |
Non-controlling interest | |
| (119,206 | ) | |
| (111,986 | ) |
Total shareholders’ equity | |
| 1,236,558 | | |
| 3,686,998 | |
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | |
$ | 8,700,490 | | |
$ | 10,354,612 | |
Intelligent Bio Solutions Inc.
Condensed Consolidated Statements of Operations
and Other Comprehensive Loss*
(Unaudited)
(Amounts in US$)
| |
Three Months Ended September 30, | |
| |
2023 | | |
2022 | |
Revenue | |
$ | 796,094 | | |
$ | - | |
Cost of revenue (exclusive of amortization shown separately below) | |
| (563,763 | ) | |
| - | |
Gross profit | |
| 232,331 | | |
| - | |
| |
| | | |
| | |
Other income: | |
| | | |
| | |
Government support income | |
| 109,871 | | |
| 311,320 | |
| |
| | | |
| | |
Operating expenses: | |
| | | |
| | |
Selling, general and administrative expenses | |
| (2,457,060 | ) | |
| (1,450,418 | ) |
Development and regulatory approval expenses | |
| (103,947 | ) | |
| (79,274 | ) |
Depreciation and amortization | |
| (307,560 | ) | |
| - | |
Total operating expenses | |
| (2,868,567 | ) | |
| (1,529,692 | ) |
Loss from operations | |
| (2,526,365 | ) | |
| (1,218,372 | ) |
| |
| | | |
| | |
Other income (expense): | |
| | | |
| | |
Interest expense | |
| (37,448 | ) | |
| (1,065 | ) |
Realized foreign exchange loss | |
| - | | |
| (2,247 | ) |
Fair value gain on revaluation of financial instrument | |
| 131,250 | | |
| - | |
Interest income | |
| 139 | | |
| 7,606 | |
Total other income | |
| 93,941 | | |
| 4,294 | |
Net loss | |
| (2,432,424 | ) | |
| (1,214,078 | ) |
Net loss attributable to non-controlling interest | |
| (7,220 | ) | |
| (5,785 | ) |
Net loss attributable to Intelligent Bio Solutions Inc. | |
$ | (2,425,204 | ) | |
$ | (1,208,293 | ) |
| |
| | | |
| | |
Other comprehensive loss, net of tax: | |
| | | |
| | |
Foreign currency translation loss | |
$ | (18,016 | ) | |
$ | (135,559 | ) |
Total other comprehensive loss | |
| (18,016 | ) | |
| (135,559 | ) |
Comprehensive loss | |
| (2,450,440 | ) | |
| (1,349,637 | ) |
Comprehensive loss attributable to non-controlling interest | |
| (7,220 | ) | |
| (5,785 | ) |
Comprehensive loss attributable to Intelligent Bio Solutions Inc. | |
$ | (2,443,220 | ) | |
$ | (1,343,852 | ) |
| |
| | | |
| | |
Net loss per share, basic and diluted* | |
$ | (1.04 | ) | |
$ | (1.62 | ) |
Weighted average shares outstanding, basic and diluted* | |
| 2,330,399 | | |
| 744,495 | |
* |
Common Stock and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1 for 20 reverse stock split effected on February 9, 2023, throughout the condensed consolidated financial statement unless otherwise stated. |
v3.23.3
Cover
|
Nov. 08, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Nov. 08, 2023
|
Entity File Number |
001-39825
|
Entity Registrant Name |
INTELLIGENT
BIO SOLUTIONS INC.
|
Entity Central Index Key |
0001725430
|
Entity Tax Identification Number |
82-1512711
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
142
West, 57th Street
|
Entity Address, Address Line Two |
11th
Floor
|
Entity Address, City or Town |
New
York
|
Entity Address, State or Province |
NY
|
Entity Address, Postal Zip Code |
10019
|
City Area Code |
(646)
|
Local Phone Number |
828-8258
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, $0.01 par value
|
Trading Symbol |
INBS
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Intelligent Bio Solutions (NASDAQ:INBS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Intelligent Bio Solutions (NASDAQ:INBS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024